Predicting Response to Herceptin Therapy

Clinical Cancer Research

Volumn 10, Issue 5, 2004, Pages 1559-1560

  Lipton, Allan ^a   Leitzel, Kim ^a   Ali, Suhail ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN TYROSINE KINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRASTUZUMAB;

ACCURACY; BREAST CANCER; CANCER IMMUNOTHERAPY; CHROMOSOME 17Q; CONTROLLED STUDY; CORRELATION ANALYSIS; EDITORIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE ACTIVATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; INHIBITION KINETICS; MAJOR CLINICAL STUDY; METASTASIS; PREDICTION; PRIORITY JOURNAL; PROTEIN DEGRADATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; GENES, ERBB-2; HUMANS; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 1842481945     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-1221-3     Document Type: Editorial

References (9)

1. Zabrecky, J. R., Lam, T., McKenzie, S. J., and Carney, W. The extracellular domain of p185 is released from the surface of human breast carcinoma cells, SK-BR-3. J. Biol. Chem., 266: 1716-1720, 1991.
2. Carney, W., Neumann, R., Lipton, A., Leitzel, K., and Price, C. P. Potential clinical utility of serum Her-2/neu oncoprotein levels in patients with breast cancer. Clinical Chem. 10: 1579-1598, 2003.
3. Leitzel, K., Teramoto, Y., Sampson, E., Mauceri, J., Langton, B. C., Demers, L., Podczaski, E., Harvey, H. A., Shambaugh, S., Volas, G., Weaver, S., and Lipton, A. Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients. J. Clin. Oncol., 10: 436-443, 1992.
4. Pupa, S. M., Menard, S., Morelli, D., Pozzi, B., De Palo, G., and Colnaghi, M. I. The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene, 8: 2917-2923, 1993.
5. Carney, W. P., Neumann, R., Lipton, A., Leitzel, K., Ali, S. M., and Price, C. P. Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin. Chem., 49: 1579-1598, 2003.
6. Wong, W. L., Bajamonde, A., Nelson, B., Carney, W., and Maas, R. D. Baseline serum HER-2 (sHER2) levels in the pivotal herceptin breast cancer trials: a comparison of 2 ELISA methods. Proc. Am. Soc. Clin. Oncol. 19: 77a, 2000.
7. Esteva, F. J., Valero, V., Booser, D., Guerra, L. T., Murray, J. L., Pusztai, L., et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J. Clin. Oncol., 20: 1800-1808, 2002.
8. Hoopmann, M., Neumann, R., Tanasale, T., and Schondorf, T. HER-2/neu determination in blood plasma of patients with HER-2/neu overexpressing metastasized breast cancer: a longitudinal study. Anticancer Res., 23: 1031-1034, 2003.
9. Dnistrian, A. M., Schwartz, M. K., Schwartz, D. C., Ghani, F., and Kish, L. Significance of serum HER-2/neu oncoprotein, CA 15-3, and CEA in the clinical evaluation of metastatic breast cancer. J. Clin. Ligand Assay, 25: 215-220, 2002.